Skip to main content
SpringerLink
Log in

Management of the Patient with Severe Refractory Rheumatoid Arthritis

Are the Newer Treatment Options Worth Considering?

  • Disease Management
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Rheumatoid arthritis (RA) is a chronic, inflammatory, autoimmune disease leading to joint destruction. It is the most common cause of potentially treatable disabilities. The outcome of the disease varies from very mild to a refractory, rapidly progressive type with a high mortality rate. In recent years, profound changes in the traditional paradigms of RA therapy have been introduced. Instead of a therapeutically progressive approach, aggressive therapy is recommended for aggressive forms of RA. It has forced us to remodel the traditional treatment pyramid, and to start new strategies such as saw-tooth or step-down-bridge schedules. The last 10 years have seen wide acceptance of immunosuppressive therapy. These agents hold much promise for the further treatment of RA. A few years ago it seemed that we would be unable to influence the long term outcome in RA, but today the development of new drugs and techniques has increased our chances of fighting RA, and prospects for the future are even more promising.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pincus T. Rheumatoid arthritis: a medical emergency? Scand J Rheumatol 1994; 23: 21–30

    Article  Google Scholar 

  2. Vandenbroucke JP, Hazevoet HM, Cats A. Survival and cause of death in rheumatoid arthritis: a 25-year prospective follow-up. J Rheumatol 1984; 11: 158–61

    PubMed  CAS  Google Scholar 

  3. Kvalvik AG, Jones MA, Symmons DPM. Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992. Scand J Rheumatol 2000; 29: 29–37

    Article  PubMed  CAS  Google Scholar 

  4. Gilliand BC. Rheumatoid arthritis: a model of chronic inflammation. In: Wolf HP, Fleckenstein A, Philipp E, editors. Drug research in the 21 st century. New York (NY): Springer, 1995: 43–50

    Google Scholar 

  5. Liang MH. Costs and outcomes in rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1984; 27: 522–9

    Article  PubMed  CAS  Google Scholar 

  6. Pincus T. Clinical observations often provide more accurate information concerning the long-term natural history and results than structured research studies. Rheumatol Eur 1995; 2 Suppl. : 179–84

    Google Scholar 

  7. Boers M, Tugwell P, Felstone DT, et al. WHO and IL-R core end points for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol 1994; 21: 86–9

    Google Scholar 

  8. Weinblatt ME. The role of current strategies in the future treatment of rheumatoid arthritis. Rheumatology (Oxf) 1999; 38 Suppl. 2: 19–23

    Google Scholar 

  9. Janossy G, Duke O, Poulter LW, et al. Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation. Lancet 1981; II: 839–42

    Article  Google Scholar 

  10. Kavanaugh A. Antiadhesion therapy in rheumatoid arthritis. Bio-Drugs 1997; 7 (2): 119–33

    CAS  Google Scholar 

  11. Allavena P, Piemonti L, Longoni D. IL10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 1998; 28: 359–69

    Article  PubMed  CAS  Google Scholar 

  12. Colville-Nash PR, Scott DL. Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis 1992; 51: 919–25

    Article  PubMed  CAS  Google Scholar 

  13. Girard J-P, Springer TA. High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. Immunol Today 1995; 16: 449–57

    Article  PubMed  CAS  Google Scholar 

  14. Yanni G, Whelan A, Feighery C, et al. Morphometric analysis of synovial membrane blood vessels in rheumatoid arthritis: association with the immunohistologic features, synovial fluid cytokine levels and clinical course. J Rheumatol 1993; 20: 634–8

    PubMed  CAS  Google Scholar 

  15. Ziff M. Role of the endothelium in chronic inflammatory synovitis. Arthritis Rheum 1991; 34: 1345–52

    Article  PubMed  CAS  Google Scholar 

  16. Chikanza IC, Jawed S, Naughton D, et al. Why do we need new treatments for rheumatoid arthritis? J Pharm Pharmacol 1998; 50: 357–69

    Article  PubMed  CAS  Google Scholar 

  17. Murray KM, Dahl SL. Recombinant human tumor necrosis factor (p75) Fc fusion protein (TNFR: Fc) in rheumatoid arthritis. Ann Pharmacother 1997; 31: 1335–8

    PubMed  CAS  Google Scholar 

  18. Ahmadzadeb N, Shingu M, Nobunaga M. The effect of recombinant tumor necrosis factor-alpha on Superoxide and metalloproteinase production by synovial cells and chondrocytes. Clin Exp Rheumatol 1990; 8: 387–91

    Google Scholar 

  19. Baert F, Peeters M, D’Haens G, et al. Impressive histologic improvement after TNF antibody (cA2) therapy in active Crohn’s disease [abstract]. Gut 1996; 39 Suppl. 1: A17

    Google Scholar 

  20. MacNaul KL, Chartrain N, Lark M, et al. Differential effects of IL-1 and TNF alpha on the expression of stromelysin, collagenase and then natural inhibitor, TIMP, in rheumatoid synovial fibroblasts. Matrix 1992; 1 Suppl. : 198–9

    PubMed  CAS  Google Scholar 

  21. Shingu M, Nagai Y, Isayama T, et al. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin Exp Immunol 1993; 94: 145–9

    Article  PubMed  CAS  Google Scholar 

  22. Taylor PC, Chapman P, Elliott MJ, et al. Reduced granulocyte traffic and chemotactic gradients in rheumatoid joints following anti-TNFα therapy [abstract]. Arthritis Rheum 1997; 40 Suppl. : S80

    Article  Google Scholar 

  23. Moreland LW. Recent advances in anti-tumour necrosis factor (TNF) therapy in rheumatoid arthritis. BioDrugs 1999; 11 (3): 201–10

    Article  PubMed  CAS  Google Scholar 

  24. Onrust SV, Lamb HM. Infliximab: a review of its use in Crohn’s disease and rheumatoid arthritis. BioDrugs 1998; 10 (5): 397–422

    Article  PubMed  CAS  Google Scholar 

  25. Rau R, Simianer S, Weier R, et al. Effective combination of the fully human anti-TNF antibody D2E7 and methotrexate in active rheumatoid arthritis [abstract no. 907]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6–11; Glasgow

  26. Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNFa monoclonal antibody cA2 binds recombinant transmembrane TNFα and activates immune effector functions. Cytokine 1995; 7 (3): 251–9

    Article  PubMed  CAS  Google Scholar 

  27. Siegel SA, Shealy DJ, Nakada MT. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vitro. Cytokine 1995; 7 (1): 15–25

    Article  PubMed  CAS  Google Scholar 

  28. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30 (16): 1443–53

    Article  PubMed  CAS  Google Scholar 

  29. Elliott MJ, Maini RN, Feldman M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor-α (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344: 1125–7

    Article  PubMed  CAS  Google Scholar 

  30. Kavanaugh AF, Cush JJ, St Clair EW, et al. Anti-TNFα monoclonal antibody (mAb) treatment of rheumatoid arthritis (RA) patients with active disease on methotrexate (MTX): results of double-blind, placebo-controlled multicenter trial [abstract]. Arthritis Rheum 1996 Sep; 39 Suppl. : 123

    Article  Google Scholar 

  31. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41 (9): 1552–63

    Article  PubMed  CAS  Google Scholar 

  32. Antoni C, Maini R, Breedveld F, et al. Subgroup analyses show consistent clinical benefit in a 30-week double blind trial (attract) with an anti-TNFα monoclonal antibody, infliximab, in rheumatoid arthritis patients on methotrexate [abstract no. 905]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6–11; Glasgow

  33. Maini RN, Smolen J, Breedveld F, et al. Anti-TNFa monoclonal antibody, infliximab (cA2, remicade™), in active rheumatoid arthritis combined with methotrexate therapy: results of a phase III trial at 30 weeks [abstract no. OP9]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6–11; Glasgow

  34. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 1932–9

    Article  PubMed  CAS  Google Scholar 

  35. Banner DW, D’Arcy A, Janes W, et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993; 73: 431–45

    Article  PubMed  CAS  Google Scholar 

  36. Brockhaus M, Schoenfeld HJ, Schlager EJ, et al. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A 1990; 87: 3127–31

    Article  PubMed  CAS  Google Scholar 

  37. Chikanza IC, Roux Lombard P, Dayer JM, et al. Tumor necrosis factor soluble receptors behave as acute phase reactants following surgery on patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis. Clin Exp Immunol 1993; 92: 19–22

    Article  PubMed  CAS  Google Scholar 

  38. Roux Lombard P, Punze L, Hasler F, et al. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum 1993; 36: 485–9

    Article  Google Scholar 

  39. Cooksey LJ. A TNF-receptor blocker for treating patients with refractory rheumatoid arthritis. Formulary 1999; 34: 211–9

    Google Scholar 

  40. Goldenberg MM. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Therapeutics 1999; 21 (1): 75–87

    Article  CAS  Google Scholar 

  41. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130: 478–86

    PubMed  CAS  Google Scholar 

  42. Røgind H, Qvistgaard E, Graff LB, et al. Ultrasonographic changes in relation to clinical observations after treatment of rheumatoid arthritis (RA) with Enbrel® (TNF-α receptors, TNR) [abstract no. 410]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6–11; Glasgow

  43. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340 (4): 253–9

    Article  PubMed  CAS  Google Scholar 

  44. Weinblatt ME. Long term and phase III treatment of DMARD-failing rheumatoid arthritis patients with TNF receptor p75 Fc fusion protein (TNFR: Fc; Enbrel) [abstract no. 572]. American College of Rheumatology 61 st National Scientific Meeting; 1997 Nov 9; Washington, DC

  45. Jorgensen C, Apparailly F, Sany J. Immunological evaluation of cytokine and anticytokine immunotherapy in vivo: what we have learnt? Ann Rheum Dis 1999; 58: 136–41

    Article  PubMed  CAS  Google Scholar 

  46. Besedovsky H, del Roy A, Sorkin E, et al. Immunoregulatory feedback between Il-1 and the glucocorticoid hormones. Science 1986; 233: 652–66

    Article  PubMed  CAS  Google Scholar 

  47. Drevlow BE, Lovis R, Haag MA, et al. Recombinant human interleukin-1 receptor type 1 in the treatment of patients with active RA. Arthritis Rheum 1996; 39: 257–65

    Article  PubMed  CAS  Google Scholar 

  48. Lebsack ME, Paul CC, Bloedow DC, et al. Subcutaneous IL-1 receptor antagonists in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1991; 34 Suppl. : 45

    Google Scholar 

  49. Lebsack ME, Paul CC, Martindale JJ, et al. A dose- and regimen-ranging study of IL-1 receptor antagonist in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1993; 36 Suppl. : 39

    Google Scholar 

  50. Lorenz HM, Kalden JR. Biological agents in rheumatoid arthritis. BioDrugs 1998; 9: 303–24

    Article  PubMed  CAS  Google Scholar 

  51. Bresnihan B, Lookabaugh J, Witt K, et al. Treatment with recombinant human interleukin-1 receptor antagonist in rheumatoid arthritis: results of a randomized double-blind, placebo-controlled multicenter trial [abstract]. Arthritis Rheum 1996; 39 Suppl. : 73

    Article  Google Scholar 

  52. Campion GV, Lebsack ME, Lookabaugh J, et al. IL-1RA Arthritis Study Group. Dose range and dose frequency study of recombinant human IL-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 1092–101

    Article  PubMed  CAS  Google Scholar 

  53. Watt I, Cobby M. Recombinant human IL-1 receptor antagonist reduces the rate of joint erosion in rheumatoid arthritis [abstract]. Arthritis Rheum 1996; 39 Suppl. : 123

    Google Scholar 

  54. Isomaki P, Luukkanes R, Saario R, et al. Interleukin-10 functions as an anti inflammatory cytokine in rheumatoid arthritis. Arthritis Rheum 1996; 39: 386–95

    Article  PubMed  CAS  Google Scholar 

  55. Breedveld FC. Future trends in the treatment of rheumatoid arthritis: cytokine targets. Rheumatology (Oxf) 1999; 38 Suppl. 2: 11–3

    CAS  Google Scholar 

  56. Koopman WJ, Gay S. Do nonimmunologically mediated pathways play a role in the pathogenesis of rheumatoid arthritis? Rheum Dis Clin North Am 1993; 19: 107–22

    PubMed  CAS  Google Scholar 

  57. Moreland LW, Koopman WJ. Biologic agents as potential therapies for treatment of autoimmune disease. In: Koopman WJ, editor. Arthritis and allied conditions. 13th ed. Baltimore (MD): Williams and Wilkins, 1997: 777–809

    Google Scholar 

  58. Lapadula G, Iannone F, Zuccaro C, et al. Recovery of erosive rheumatoid arthritis after human immunodeficiency virus-1 infection and hemiplegia. J Rheumatol 1997; 24 (4): 747–51

    PubMed  CAS  Google Scholar 

  59. Sigal NH, Dumont FJ. Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Ann Rev Immunol 1992; 10: 519–60

    Article  CAS  Google Scholar 

  60. Yocum DE. Cyclosporine, FK-506, rapamycin, and other immunomodulators. Rheum Dis Clin North Am 1996; 22: 133–54

    Article  PubMed  CAS  Google Scholar 

  61. Moris RE. Rapamycin: FK-506’s fraternal twin or distant cousin? Immunol Today 1991; 12: 137–40

    Google Scholar 

  62. Kay JE, Kromwel L, Doe SEA, et al. Inhibition of T and B lymphocytes proliferation by rapamycin. Immunology 1991; 72: 544–9

    PubMed  CAS  Google Scholar 

  63. Lin CS, Boltz RC, Siekierka JJ, et al. FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes. Cell Immunol 1991; 133: 269–84

    Article  PubMed  CAS  Google Scholar 

  64. Hermann B, Meuller W. Die therapie der chronischen polyarthritis mit cyclosporin A, einens neuen immun-suppressivum. Aktuel Rheumatol 1979; 4: 173–86

    Google Scholar 

  65. Kim Wu, Cho ML, Kim SI, et al. Divergent effect of cyclosporine on Thl/Th2 type cytokines in patients with severe refractory rheumatoid arthritis. J Rheumatol 2000; 27: 324–31

    PubMed  CAS  Google Scholar 

  66. Pasero G, Ferraccioli GF, Portioli I. Risks and benefit of lowdosage cyclosporin in rheumatoid arthritis. BioDrugs 1997; 7: 376–85

    Article  PubMed  CAS  Google Scholar 

  67. Arita C, Hotokebuchi T, Miyahara H, et al. Inhibition by FK-506 of established lesions of collagen-induced arthritis in rats. Clin Exp Immunol 1990; 82: 456–61

    Article  PubMed  CAS  Google Scholar 

  68. Carlson RP, Hartman DA, Tomchek LA, et al. Rapamycin, a potential disease-modifying antiarthritic drug. J Pharmacol Exp Ther 1993; 266: 1125–38

    PubMed  CAS  Google Scholar 

  69. Miyahara H, Hotokebachi T, Arita C, et al. Comparative studies of the effects of FK-506 and Cyclosporine A on passively transferred collagen-induced arthritis in rats. Clin Immunol Immunopathol 1991; 60: 278–88

    Article  PubMed  CAS  Google Scholar 

  70. Gremillion RB, Posever JO, Manek N, et al. Tacrolimus (FK506) in the treatment of severe, refractory rheumatoid arthritis: initial experience in 12 patients. J Rheumatol 1999; 26: 2332–6

    PubMed  CAS  Google Scholar 

  71. Plosker GL, Wagstaff AJ. Leflunomide. Clin Immunother 1996; 6 (4): 300–5

    Article  Google Scholar 

  72. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999; 159: 2542–50

    Article  PubMed  CAS  Google Scholar 

  73. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind randomised, multicentre trial. Lancet 1999; 353: 259–66

    Article  PubMed  CAS  Google Scholar 

  74. Emery P, Breedveld F, Lemmel EM, et al. A phase III, randomized, double-blind study of leflunomide versus methotrexate in rheumatoid arthritis [abstract no. 399]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6–11; Glasgow

  75. Furst D, Weaver A, Strand V. A comparison of leflunomide, placebo, and methotrexate for the treatment of active rheumatoid arthritis [abstract no. 398]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6–11; Glasgow

  76. Kalden JR, Smolen JS, Rozman B. Leflunomide vs placebo vs sulfasalazine in rheumatoid arthritis: impact on functional ability [abstract no. 887]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6–11; Glasgow

  77. Larsen A, Emery P, Loew-Friedrich I, et al. Comparison of radiographic endpoints in rheumatoid arthritis patients treated with leflunomide or methotrexate [abstract no. 86]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6–11; Glasgow

  78. Schiff M, Kaine J, Sharp J, et al. Retardation of radiographic disease progression in active rheumatoid arthritis with leflunomide compared to placebo and methotrexate [abstract no. 886]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6–11; Glasgow

  79. Euqui EM, Almquist SJ, Muller CS et al. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxy guanosine nucleotide depletion. Scand J Immunol 1991; 33: 1616–73

    Google Scholar 

  80. Schiff MH, Goldmlum R, Rees MMC. New DMARD, mycophenolate mofetil, effectively treats refractory rheumatoid arthritis patients for one year [abstract]. Arthritis Rheum 1991; 34 Suppl. : 89

    Article  Google Scholar 

  81. Larsen A, Petersson I, Svensson B. Podophyllum derivatives (CPH 82) compared with placebo in treatment of rheumatoid arthritis. Br J Rheumatol 1989; 28: 124–7

    Article  PubMed  CAS  Google Scholar 

  82. Bjørneboe O, Moen F, Nygaard H, et al. CPH-82 (Reumacon®) versus auranofin (Ridaura®): a 36-week study of their respective onset of action rates in RA. Scand J Rheumatol 1998; 27: 26–31

    Article  PubMed  Google Scholar 

  83. Gudmundsdüttir E, Jünsson H. Reumacon (CPH 82) in refractory inflammatory arthritis [abstract no. 889]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6–11; Glasgow

  84. Petersson I, Hedin P-J. Treatment of rheumatoid arthritis with reumacon: a placebo double-blind controlled study [abstract]. Scand J Rheumatol 1990; 19 Suppl. 85: 48

    Google Scholar 

  85. Korpela M, Tiitinen S, Nissilä M. CPH 82 versus azathioprine in the treatment of rheumatoid arthritis and reactive (AA) amyloidosis [abstract no. 888]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6–11; Glasgow

  86. Evans CH, Robbins PD, Ghivizzani SD, et al. Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 1996; 7: 1261–80

    Article  PubMed  CAS  Google Scholar 

  87. Evans CH, Whalen JD, Ghivizzani SC, et al. Gene therapy in autoimmune diseases. Ann Rheum Dis 1998; 57: 125–7

    Article  PubMed  CAS  Google Scholar 

  88. Boyle DL, Nguyen KH, Zhuang S, et al. Intra-articular IL-4 gene therapy in arthritis: anti-inflammatory effect and enhanced th2 activity. Gene Ther 1999; 6: 1911–8

    Article  PubMed  CAS  Google Scholar 

  89. Evans CH, Robbins PD. Gene therapy of arthritis. Intern Med 1999 Mar; 38: 233–9

    Article  PubMed  CAS  Google Scholar 

  90. MacCarthy M. Gene therapy for rheumatoid arthritis starts clinical trials. Lancet 1996; 348: 323

    Article  Google Scholar 

  91. Moreland LW, Koopman WJ. Vaccination against rheumatoid arthritis: concepts and progress. BioDrugs 1997; 8 (2): 87–95

    Article  PubMed  CAS  Google Scholar 

  92. Gustafsson K, Karlsson M, Anderson L, et al. Structures on the I-A molecule predisposing to susceptibility to type II collagen-induced autoimmune arthritis. Eur J Immunol 1990; 20: 2127–31

    Article  PubMed  CAS  Google Scholar 

  93. Lider O, Karin N, Shinitsky M, et al. Therapeutic vaccination against adjuvant arthritis using autoimmune T-cells treated with hydrostatic pressure. Proc Natl Acad Sci U S A 1987; 84: 4577–80

    Article  PubMed  CAS  Google Scholar 

  94. Lohse AW, Bakker NPM, Hermann E, et al. Induction of an anti-vaccine response by T-cell vaccination in non-human primates and humans. J Autoimmun 1993; 1 (1): 121–30

    Article  Google Scholar 

  95. Mor F, Lohse AW, Karin N, et al. Clinical modeling of T-cell vaccination against autoimmune disease in rats: selection of antigen-specific T-cells using a mitogen. J Clin Invest 1990; 85: 1594–8

    Article  PubMed  CAS  Google Scholar 

  96. Moreland LW, HeckJr LW, Koopman WJ, et al. Vßl7 T-cell receptor peptide vaccine: results of phase I dose-finding study in patients with rheumatoid arthritis. Ann N Y Acad Sci 1995; 756: 211–4

    Article  PubMed  CAS  Google Scholar 

  97. Prakken B, Samodal R, Bonnin D, et al. Immunomodulatory effects of treatment with a ’shared epitope’ peptide in patients with rheumatoid arthritis [abstract no. OP8]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6–11; Glasgow

  98. Combe B, Cosso B, Clot J, et al. Human placenta-eluted gammaglobulins in immunomodulating treatment of rheumatoid arthritis. Am J Med 1985; 78: 920–8

    Article  PubMed  CAS  Google Scholar 

  99. Sany J, Clot J, Bonneau M, et al. Immunomodulating effect of human placenta-eluted gamma globulins in rheumatoid arthritis. Arthritis Rheum 1982; 25: 17–24

    Article  PubMed  CAS  Google Scholar 

  100. Bendtzen K, Hansen MB, Ross C, et al. Cytokines and autoantibodies to cytokines. Stem Cells (Dayt) 1995; 13: 206–22

    Article  CAS  Google Scholar 

  101. Bendtzen K, Svenson M, Hansen M. Autoantibodies to cytokines in IVIG. J Rheumatol 1993; 20: 2176–7

    PubMed  CAS  Google Scholar 

  102. Kondo N, Kasahara K, Kameyama T, et al. Intravenous immunoglobulins suppress immunoglobulin productions be suppressing Ca (2+)-dependent signal transduction through Fc gamma receptors in B lymphocytes. Scand J Immunol 1994; 40: 37–42

    Article  PubMed  CAS  Google Scholar 

  103. Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 1993; 91: 602–7

    Article  PubMed  CAS  Google Scholar 

  104. Qi M, Schifferli JA. Inhibition of complement activation by intravenous immunoglobulins. Arthritis Rheum 1995; 38 (1): 146

    Article  PubMed  CAS  Google Scholar 

  105. Moynier M, Cosso B, Brochier J, et al. Identification of class II HLA alloantigens in placenta-eluted gammaglobulins used for treating rheumatoid arthritis. Arthritis Rheum 1987; 30: 375–81

    Article  PubMed  CAS  Google Scholar 

  106. Nydegger UE, Sultan Y, Kazatchkine MD. The concept of anti-idiotypic regulation of selected autoimmune diseases by intravenous immunoglobulin. Clin Immunol Immunopathol 1989; 53: 72–82

    Article  Google Scholar 

  107. Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Saf 1993; 9: 254–62

    Article  PubMed  CAS  Google Scholar 

  108. Schiavotto C, Ruggeri M, Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica 1993; 78: 35–40

    PubMed  CAS  Google Scholar 

  109. Zeuner RA, Euler HH, Schroeder JO. High dose intravenous immunoglobulin in autoimmune rheumatic disorders. Bio-Drugs 1997; 8: 371–86

    CAS  Google Scholar 

  110. Pratt W, Heck L, Moreland LW, et al. Safety and immunogenicity of single intramuscular injection of a synthetic HLA-DR4/1 peptide vaccine with alum adjuvant in rheumatoid arthritis patients [abstract]. Arthritis Rheum 1995; 38 Suppl. : S281

    Google Scholar 

  111. Trentham DE, Dynesius-Trentham RA, Orav EJ, et al. Effects of oral administration of auto antigens. Annu Rev Immunol 1994; 12: 809–37

    Article  PubMed  Google Scholar 

  112. Kavanaugh AF, Davis LS, Nichols LA, et al. Retreatment of RA patients with an anti-ICAM-1 monoclonal antibody [abstract]. Arthritis Rheum 1994; 38: S280

    Google Scholar 

  113. Kavanaugh AF, Davis LS, Nichols LA, et al. Treatment of refractory rheumatoid arthritis with monoclonal antibody to ICAM-1. Arthritis Rheum 1994; 37: 992–9

    Article  PubMed  CAS  Google Scholar 

  114. Odell JR, Haire CE, Palmer W, et al. Treatment of early rheumatoid arthritis with minocycline or placebo: result of a double blind placebo controlled trial. Arthritis Rheum 1997; 40: 842–8

    Article  CAS  Google Scholar 

  115. Emery P. Early rheumatoid arthritis: therapeutic strategies. Scand J Rheumatol Suppl 1994; 100: 3–7

    Article  PubMed  CAS  Google Scholar 

  116. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30 (11): 1205–13

    Article  PubMed  CAS  Google Scholar 

  117. Silver J, Goyert SM. Epitopes are the functional units of Ia molecules and form the molecular basis for disease susceptibility. In: Ferrone S, Solheim BG, Moller E, editors. Human class II histocompatibility antigens. Berlin: Springer-Verlag, 1985: 32–48

    Google Scholar 

  118. Amos RS, Constable TS, Crockson RA, et al. Rheumatoid arthritis: relation of serum C-reactive protein and erythrocyte sedimentation rates to radiographic changes. BMJ 1977; 16: 195–7

    Article  Google Scholar 

  119. Davis MJ, Dawes PT, Fowler PD, et al. The association and predictive value of the complex immunoglobulin A-alphal antitrypsin in the development of erosions in early rheumatoid arthritis. Scand J Rheumatol 1991; 20: 23–7

    Article  PubMed  CAS  Google Scholar 

  120. deCarralno A, Grandal H. Radiographic progression of RA related to some clinical and laboratory parameters. Acta Radiol Diagn (Stockh) 1980; 21: 551–5

    Google Scholar 

  121. Lacki JK, Porawska W, Mackiewicz U, et al. Changes in agalactosyl IgG levels correlate with radiological progression in early rheumatoid arthritis. Ann Med 1996; 28: 265–9

    Article  PubMed  CAS  Google Scholar 

  122. Lacki JK, Schochat T, Porawska W, et al. Does the serum level of IgA-AT complex correlate with radiological progression of early RA? Rheumatol Int 1995; 14: 227–30

    Article  PubMed  CAS  Google Scholar 

  123. Larsen A. The relation of radiographie changes to serum acute phase proteins and rheumatoid factor in 200 patients with rheumatoid arthritis. Scand J Rheumatol 1988; 17: 123–9

    Article  PubMed  CAS  Google Scholar 

  124. Scott DL, Coulton BL, Popert AJ. Long-term progression of joint damage in rheumatoid arthritis. Ann Rheum Dis 1986; 45: 373–8

    Article  PubMed  CAS  Google Scholar 

  125. Sjoblom KG, Saxne S, Pettersson H, et al. Factors related to the progression of the joint destruction in rheumatoid arthritis. Scand J Rheumatol 1994; 13: 21–7

    Article  Google Scholar 

  126. van Zeben D, Breedveld FC. Prognostic factors in rheumatoid arthritis. J Rheumatol Suppl 1996; 44: 31–3

    PubMed  Google Scholar 

  127. van Zeben D, Rook GA, Hazes JM, et al. Early agalactosylation of IgG is associated with a more progressive disease course in patients with rheumatoid arthritis: results of a follow-up study. Br J Rheumatol 1994; 33: 36–43

    Article  PubMed  Google Scholar 

  128. Wilske KR, Healey LA. Remodeling the pyramid: concept whose time has come. J Rheumatol 1989; 16: 565–7

    PubMed  CAS  Google Scholar 

  129. Fries JF. Reevaluating the therapeutic approach to rheumatoid arthritis: the saw-tooth strategy. J Rheumatol 1990; 22 Suppl. : 12–5

    CAS  Google Scholar 

  130. Wilske KR. Inverting the therapeutic pyramid: observation and recommendation on new directions in rheumatoid arthritis therapy based on the author’s experience. Semin Arthritis Rheum 1993; 23 Suppl. 1: 11–8

    Article  PubMed  CAS  Google Scholar 

  131. Asten PM, Barrett JH, Symmons DPM. Rheumatic disease patients treated with immunosuppressants have an increased risk of developing certain types of malignancy compared to the general population [abstract no. 357]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6–11; Glasgow

  132. Iannuzzi L, Dawson N, Zein N, et al. Does drug therapy slow radiographie deterioration in rheumatoid arthritis? N Engl J Med 1983; 309 (17): 1023–8

    Article  PubMed  CAS  Google Scholar 

  133. Karateev D, Ivanova M, Akimova T. Death and treatment in patients with rheumatoid arthritis [abstract no. 358]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6–11; Glasgow

  134. Outcome in rheumatoid arthritis. Proceedings of a symposium. Droitwich, Worcestershire, May 8th and 9th, 1987. Br J Rheumatol 1988; 27 Suppl. 1: 1-77

  135. Pincus T. Rheumatoid arthritis: disappointing long-term outcomes despite successful clinical trials. J Clin Epidemiol 1988; 41: 1037–41

    Article  PubMed  CAS  Google Scholar 

  136. Kushner I. Does aggressive therapy of rheumatoid arthritis affect outcome? J Rheumatol 1989; 16: 1–4

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

I would like acknowledge the help given to me by Professor Geoffrey Shaw during the preparation of this paper.

Author information

Authors and Affiliations

  1. Department of Rheumatology and Clinical Immunology, Karol Marcinkowski University School of Medical Sciences, Winogrady 144, 61-626, Poznan, Poland

    Jan K. Lacki

Authors
  1. Jan K. Lacki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jan K. Lacki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lacki, J.K. Management of the Patient with Severe Refractory Rheumatoid Arthritis. BioDrugs 13, 425–435 (2000). https://doi.org/10.2165/00063030-200013060-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200013060-00006

Keywords

Search

Navigation